全文获取类型
收费全文 | 323篇 |
免费 | 30篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 3篇 |
基础医学 | 76篇 |
临床医学 | 19篇 |
内科学 | 61篇 |
皮肤病学 | 7篇 |
神经病学 | 3篇 |
外科学 | 40篇 |
综合类 | 1篇 |
预防医学 | 39篇 |
药学 | 12篇 |
中国医学 | 1篇 |
肿瘤学 | 89篇 |
出版年
2022年 | 3篇 |
2021年 | 4篇 |
2020年 | 5篇 |
2019年 | 3篇 |
2018年 | 3篇 |
2017年 | 2篇 |
2015年 | 5篇 |
2014年 | 3篇 |
2013年 | 6篇 |
2012年 | 16篇 |
2011年 | 13篇 |
2010年 | 2篇 |
2009年 | 5篇 |
2008年 | 7篇 |
2007年 | 8篇 |
2006年 | 14篇 |
2005年 | 10篇 |
2004年 | 8篇 |
2003年 | 11篇 |
2002年 | 12篇 |
2001年 | 9篇 |
2000年 | 12篇 |
1999年 | 22篇 |
1998年 | 7篇 |
1997年 | 4篇 |
1996年 | 3篇 |
1995年 | 7篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 18篇 |
1991年 | 14篇 |
1990年 | 14篇 |
1989年 | 9篇 |
1988年 | 13篇 |
1987年 | 8篇 |
1986年 | 7篇 |
1985年 | 3篇 |
1984年 | 12篇 |
1983年 | 7篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1979年 | 7篇 |
1978年 | 5篇 |
1977年 | 2篇 |
1975年 | 2篇 |
1974年 | 2篇 |
1971年 | 1篇 |
1970年 | 2篇 |
1967年 | 1篇 |
排序方式: 共有353条查询结果,搜索用时 0 毫秒
351.
Chêne G Penault-Llorca F Raoelfils I Bignon YJ Ray-Coquard I Seffert P Dauplat J 《Gynécologie, obstétrique & fertilité》2011,39(4):216-223
Ovarian carcinogenesis and the early stages of malignant transformation are limited because of the lack of a candidate precursor. There have been several proposed hypotheses: first, ovary and the ovarian surface epithelium and more recently observations have increasingly focused attention of the Fallopian tube. Moreover, molecular genetic analysis has designed two main pathways of tumorogenesis. In this review, we discuss the different and perhaps complementary hypotheses about ovarian carcinogenesis. 相似文献
352.
Laetitia Delort Samir Satih Fabrice Kwiatkowski Yves-Jean Bignon Dominique J Bernard-Gallon 《Nutrition and cancer》2013,65(2):243-251
Breast cancer has become the most frequent cancer among women in Westernized countries. The majority of breast cancers are due to low penetrance genes, which can act with environmental factors, particularly nutrition. Polymorphisms in gene coding for xenobiotic and estrogen metabolic pathways could increase individual cancer susceptibility and lead to the indication of individuals at higher cancer risk. A population-based, case-control study consisting of 911 breast cancer cases and 1,000 healthy control cases was performed. The association between 11 single nucleotide polymorphisms (SNP) in 7 genes and breast cancer risk was investigated in a multigenic model. The CYP1B1-432 Leu-Val and Val-Val genotypes significantly increased risk [odds ratio (OR) = 1.23, 95% confidence interval (CI) = 1.08–1.39; OR = 1.51, 95% CI = 1.17–1.94, respectively] similarly as observed with CYP1B1-453 (Asn-Ser genotype: OR = 1.17, 95% CI = 1.00–1.37; Ser-Ser genotype: OR = 1.38, 95% CI = 1.00–1.89). We showed that catechol-O-methyltransferase (COMT) could modulate the risk conferred by CYP1B1, ESR, GSTP1, and NAT2 acetylation phenotype. Additionally, a higher risk conferred by the variant for COMT was noted only for individuals presenting a high waist-to-hip ratio (COMT Val-Met, OR = 1.60, 95% CI = 1.04–2.44; COMT Met-Met, OR = 1.57, 95% CI = 0.98–2.53), suggesting a relationship with abdominal adiposity. In conclusion, COMT constitutes a crucial element in estrogen metabolism by regulating carcinogen metabolites elimination and, consequently, is a major factor in breast cancer risk. 相似文献
353.
Bignon E Alonso R Arnone M Boigegrain R Brodin R Gueudet C Héaulme M Keane P Landi M Molimard JC Olliero D Poncelet M Seban E Simiand J Soubrié P Pascal M Maffrand JP Le Fur G 《The Journal of pharmacology and experimental therapeutics》1999,289(2):752-761
SR146131 is a potent and selective agonist at cholecystokinin subtype 1 (CCK1) receptors in vitro. The present study evaluates the activity of the compound in vivo. SR146131 completely inhibited gastric and gallbladder emptying in mice (ED50 of 66 and 2.7 micrograms/kg p.o., respectively). SR146131 dose dependently reduced food intake in fasted rats (from 0.1 mg/kg p.o.), in nonfasted rats in which food intake had been highly stimulated by the administration of neuropeptide Y (1-36) (from 0.3 mg/kg p.o.), in fasted gerbils (from 0.1 mg/kg p.o.), and in marmosets maintained on a restricted diet (from 3 mg/kg p.o.). SR146131 (10 mg/kg p.o.) also increased the number of Fos-positive cells in the hypothalamic paraventricular nucleus of rats. Locomotor activity of mice was reduced by orally administered SR146131 (from 0.3 mg/kg p.o.). When administered intrastriatally, SR146131 elicited contralateral turning behavior in mice. Furthermore, orally administered SR146131 (0.3-10 mg/kg), also reduced the levels of cerebellar cyclic GMP. Finally, SR146131 (0.1 microgram/kg to 1 mg/kg, p.o.) significantly and dose dependently antagonized fluphenazine-induced mouth movements in rats. The CCK1 antagonist SR27897B prevented all the effects of SR146131. Conversely, SR146131 was unable to elicit any agonist or antagonist effects in a model of CCK2 receptor stimulation in vivo. SR146131 is a very potent and selective nonpeptide CCK1 agonist in vivo. SR146131 is more potent than any other CCK1 agonists reported to date. Because pharmacodynamic studies suggest that SR146131 should have a high absolute bioavailability, it may be a promising drug for the treatment of eating and motor disorders in humans. 相似文献